Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Intelligent Bio Solutions Inc. (INBS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: INBS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -86.5% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.14M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 188443 | Beta 4.72 | 52 Weeks Range 1.00 - 4.00 | Updated Date 04/2/2025 |
52 Weeks Range 1.00 - 4.00 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -386.32% |
Management Effectiveness
Return on Assets (TTM) -53.26% | Return on Equity (TTM) -171.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8491285 | Price to Sales(TTM) 3.33 |
Enterprise Value 8491285 | Price to Sales(TTM) 3.33 | ||
Enterprise Value to Revenue 2.8 | Enterprise Value to EBITDA -0.91 | Shares Outstanding 4386820 | Shares Floating 4142574 |
Shares Outstanding 4386820 | Shares Floating 4142574 | ||
Percent Insiders 3.02 | Percent Institutions 14.38 |
Analyst Ratings
Rating 5 | Target Price 11.3 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Intelligent Bio Solutions Inc.
Company Overview
History and Background
Intelligent Bio Solutions Inc. (IBS) is focused on developing and commercializing rapid, point-of-care diagnostics and drug screening solutions. Founded with the goal of improving accuracy and efficiency in testing, IBS has grown through innovation and strategic partnerships. Recent milestones include product development advancements and expansion into new markets.
Core Business Areas
- Drug Screening: Developing and marketing rapid, non-invasive drug screening devices for various applications, including workplace testing and law enforcement.
Leadership and Structure
The company is led by a team of executives with experience in diagnostics and biotechnology. The organizational structure includes departments for research and development, sales and marketing, and operations.
Top Products and Market Share
Key Offerings
- Drug Screening System: A rapid, point-of-care drug screening system designed for on-site testing. Market share is difficult to specify precisely, but IBS competes with established players in the drug testing market. Competitors include Abbott Laboratories (ABT) and Thermo Fisher Scientific (TMO).
Market Dynamics
Industry Overview
The drug screening market is driven by factors such as increasing workplace drug testing regulations and demand for rapid, point-of-care testing solutions.
Positioning
IBS aims to differentiate itself through its innovative technology and ease of use, targeting specific niches within the broader drug testing market.
Total Addressable Market (TAM)
The global drug testing market is estimated to be in the billions of dollars. IBS is positioned to capture a portion of this TAM with its targeted solutions.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Rapid testing capabilities
- Point-of-care solutions
Weaknesses
- Limited brand recognition
- Smaller market share compared to established competitors
- Dependence on single revenue stream
Opportunities
- Expanding into new markets
- Developing new applications for existing technology
- Partnerships with industry leaders
Threats
- Competition from larger companies
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- ABT
- TMO
- LH
Competitive Landscape
IBS faces intense competition from larger, more established players. Its competitive advantage lies in its specific technology and niche market focus.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on previous annual reports.
Future Projections: Future projections require analyst forecasts. Expect growth with the industry's growth.
Recent Initiatives: Recent initiatives include product development advancements and strategic partnerships.
Summary
Intelligent Bio Solutions Inc. shows promise with its innovative drug screening technology, but faces challenges due to its small size and limited market presence. Its point-of-care solutions offer a competitive edge, and potential growth opportunities lie in expanding its product line and market reach. The company must navigate intense competition and regulatory hurdles to succeed. Success hinges on its ability to scale production, forge strategic partnerships, and secure funding.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
LH
Laboratory Corporation of America Holdings
LH
Laboratory Corporation of America Holdings
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (Limited Availability)
- Industry Reports
Disclaimers:
The data provided is based on available information and may not be comprehensive. Market share estimates are approximate. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intelligent Bio Solutions Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-12-23 | President & CEO Mr. Harry Simeonidis | ||
Sector Healthcare | Industry Medical Devices | Full time employees 50 | Website https://ibs.inc |
Full time employees 50 | Website https://ibs.inc | ||
Intelligent Bio Solutions Inc., a medical technology company, developing rapid, non-invasive testing, and screening solutions. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse. It also operates biosensor platform for clinical chemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York. The company operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.